Clinical Trials Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Aug 6, 2024; 12(22): 5016-5023
Published online Aug 6, 2024. doi: 10.12998/wjcc.v12.i22.5016
Serum activin A as a prognostic biomarker for community acquired pneumonia
Yu-Ting Wang, Yan Liu, Guang-Hui Zhou, Kan Liu, Yan Fen, Hui Ding
Yu-Ting Wang, Yan Liu, Guang-Hui Zhou, Kan Liu, Yan Fen, Hui Ding, Pulmonary and Critical Care Medicine, Yixing People’s Hospital of Jiangsu University, Yixing 214200, Jiangsu Province, China
Co-first authors: Yu-Ting Wang and Yan Liu
Author contributions: Ding H made substantial contributions to the conception of the work; Wang YT was the chief investigator and responsible for the data analysis; Liu Y made significant contributions to the data analysis and interpretation; Liu K, Zhou GH and Fen Y developed the trial design; All authors contributed to the writing of the final manuscript.
Institutional review board statement: This study was approved by the ethical committee of Yixing People’s Hospital (Approval No. 2018-036).
Clinical trial registration statement: This study is registered at Yixing People’s Hospital trial registry. The registration identification number is 2018-036.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
CONSORT 2010 statement: The authors have read the CONSORT 2010 statement, and the manuscript was prepared and revised according to the CONSORT 2010 statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hui Ding, Doctor, PhD, Chief Doctor, Pulmonary and Critical Care Medicine, Yixing People’s Hospital of Jiangsu University, No. 75 Tongzhen Road, Yixing 214200, Jiangsu Province, China. dh1350519@163.com
Received: April 17, 2024
Revised: May 24, 2024
Accepted: June 21, 2024
Published online: August 6, 2024
Processing time: 76 Days and 2.6 Hours
Core Tip

Core Tip: Serum activin A levels were significantly higher in community-acquired pneumonia (CAP) patients. Higher level of serum activin A was associated with the severity and poor prognosis of CAP. Activin A can be used as a more valuable biomarker of prognosis in CAP patients. Future studies are justified to explore the precise biomolecular functions of activin A in CAP.